secwatch.observer — SEC 8-K summary
======================================

Issuer:     PURE BIOSCIENCE, INC. (PURE)
CIK:        0001006028
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001493152-24-050223
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PURE Bioscience Q1 FY2025 product sales $555K, down 23% YoY; net loss per share ($0.01)
--------------------------------------------------------------------------------

- Net product sales of $555K for quarter ended Oct 31, 2024, vs $718K YoY, due to budget constraints of a large end-use customer.
- Net loss narrowed to $689K from $735K YoY; net loss per share unchanged at ($0.01).
- Excluding share-based compensation, net loss was $632K vs $655K YoY.
- CEO cites unexpected interruption in product flow to a major customer and lack of replacement revenue as reasons for the decline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006028/000149315224050223/0001493152-24-050223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006028/000149315224050223/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-050223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer